DBV Technologies Files US Application for Viaskin Peanut Patch in Children

MT Newswires · 2d ago
12:01 AM EDT, 09/30/2026 (MT Newswires) -- DBV Technologies (DBV.PA) filed a biologics license application with the US Food and Drug Administration for use of the Viaskin Peanut Patch food allergy treatment in children aged four to seven years. The late-stage biopharmaceutical company said Tuesday that it requested priority review from the regulator for the application, noting that the FDA previously issued Breakthrough Therapy Designation for the peanut patch.